Table 4.

Sensitivity analysis results in terms of incremental cost-effectiveness ratio percentage of change, differences in quality-adjusted life years, and costs in each scenario

Parameter	Δ of costs (in USD)	Δ of QALY	ICER	Percentage of change in ICER (%)
The hydroxyurea price of 0.0167 USD per capsule	13,430	0.01	1,194,054	0%
The hydroxyurea price of 0.028 USD per capsule	13,430	0.01	1,194,054	0%
Crizanlizumab with a 20% lower than the base price in the concomitant scenario	10,755	0.01	956,189	-19.92%
Crizanlizumab with a 20% lower than the base price in the concomitant scenario	10,801	0.01	872,494	-19.85%

USD: United States Dollar; QALY: Quality adjusted life years; ICER: Incremental cost effectiveness ratio